Thus far, the role of Akt inhibitors to augment the efficacy of chemotherapy in solid tumors has not been dealt with to a large extent, despite promising preclinical and clinical data [23, 24, 27–29] and should be explored further, in particular in ER positive breast cancers. This evidence concerns the gene ESR1 and breast carcinoma.